WORKS DIFFERENTLY*
THAN OTHER PILLS

*Selective TYK2 inhibitor

WORKS DIFFERENTLY*
THAN OTHER PILLS

*Selective TYK2 inhibitor
HERE'S A LOOK AT HOW IT WORKS
Moderate to severe plaque psoriasis can be really difficult to live with. It can make your skin itchy, scaly, and painful. While people may think it’s only visible on the surface of the skin, psoriasis starts inside your body.
Normally, your immune system works to protect you from infections and illness. Scientists don’t know the exact reason why, but in psoriasis, your immune system becomes overactive. This means parts of your immune system send too many inflammatory signals.
Hypothetical SOTYKTU™ (deucravacitinib) patient with moderate to severe plaque psoriasis on the scalp and arm
TYK2 is one of the molecules in your immune system that plays a key role in passing on these signals throughout your body. This can lead to inflammation, and can cause skin to build up and form plaques.
TYK2 passing on too many inflammatory signals
SOTYKTU is the only pill that selectively targets TYK2.
SOTYKTU is the only FDA-approved once-daily pill that selectively targets and blocks TYK2 signals. It is not currently known how blocking TYK2 signals works to reduce psoriasis symptoms.
SOTYKTU™ (deucravacitinib) blocking TYK2
1787-US-2200571 09/22
SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
All other trademarks are property of their respective owners.
© 2022 Bristol-Myers Squibb Company.
1787-US-2200141 09/22
This website is intended for U.S. residents
18 years of age or older.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.